

Human Noggin Protein

Cat. No. NOG-HM001



Description

Source	Recombinant Human Noggin Protein is expressed from CHO without tag. It contains Gln28-Cys232.
Accession	Q13253
Molecular Weight	The protein has a predicted MW of 23.05 kDa. Due to glycosylation, the protein migrates to 30-36 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 0.05 EU per µg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Noggin is an antagonist of bone morphogenetic proteins (BMP), being indispensable for certain developmental events. Noggin expression positively correlated with EGFR expression in both GC cell line models and The Cancer Genome Atlas human GC cohort. Targeting EGFR and its downstream pathways diminished cell proliferation which was promoted by Noggin. Noggin promotes the proliferation of GC cells by upregulating EGFR and enhancing a vicious circle formed by β catenin, EGFR, ERK and Akt.

Assay Data


Bis-Tris PAGE



Human Noggin on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC


Assay Data



The purity of Human Noggin is greater than 95% as determined by SEC-HPLC.

Cell Based Assay

Recombinant Human Noggin Bioactivity



Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells. The ED50 for this effect is 4-80 ng/mL in the presence of 50 ng/mL of recombinant Human BMP4.